Deborah A. McDowell of OAW explains how patients can prepare for hair loss before chemotherapy starts.
News|Videos|August 3, 2016
What to Consider Before Choosing a Melanoma Treatment Plan
Author(s)Claire Friedman, MD
Claire Friedman, Memorial Sloan Kettering Cancer Center, discusses some of the factors that doctors and elderly patients with melanoma should discuss before deciding on a treatment plan with immunotherapy. Immunotherapy is not one-size-fits all, and patients should be informed of the pros and cons of each option.
Advertisement
Claire Friedman, Memorial Sloan Kettering Cancer Center, discusses some of the factors that doctors and elderly patients with melanoma should discuss before deciding on a treatment plan with immunotherapy. Immunotherapy is not one-size-fits all, and patients should be informed of the pros and cons of each option.
Advertisement
Related to this article
Progression-free survival reached 14.3 months with Enhertu versus 8.3 months with chemotherapy plus Keytruda in HER2-mutant lung cancer.
Dr. Dina Khalaf breaks down three clinical trials testing oral and targeted regimens for acute myeloid leukemia and myelodysplastic syndrome.
Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.
Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.
Lunsumio added to Revlimid kept relapsed or refractory follicular lymphoma from worsening longer than Rituxan plus Revlimid in the phase 3 CELESTIMO trial.
Three new studies from WCLC 2026 show strong results in ROS1-positive NSCLC, EGFR-mutant NSCLC and relapsed small cell lung cancer, offering fresh options.
See 5 years of FDA leukemia approvals for CLL, AML and CML — new drugs, new drug classes, and how many patients they've actually helped.
Advertisement
Advertisement
Trending on CURE
1
5 Years of Leukemia Advances: A Timeline of FDA Approvals and What They Mean for Patients
2
For Patients with Polycythemia Vera, Fewer Phlebotomies Could Mean More Time Back
3
FDA Approves Inluriyo Plus Verzenio for Certain Advanced Breast Cancers
4
3 More Lung Cancer Breakthroughs From WCLC 2026
5